Brief: Nextcure Initiates Phase 1/2 Clinical Study Of NC410, A Novel Immunomedicine, For Solid Tumors
07/07/2020 21:26
July 7 (Reuters) - NextCure Inc NXTC.O :
* NEXTCURE INITIATES PHASE 1/2 CLINICAL STUDY OF NC410, A
NOVEL
IMMUNOMEDICINE, FOR SOLID TUMORS
* NEXTCURE INC - ANTICIPATES INITIAL DATA FROM PHASE 1
PORTION OF
TRIAL BY SECOND HALF OF 2021
Source text for Eikon: ID:nGNXbsc4rb
Further company coverage: NXTC.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on NextCure
See all newsBrief: Xcellon Biologics Co Acquires Gmp Manufacturing Facility From Nextcure
NextCure Inc reports results for the quarter ended June 30 - Earnings Summary
NextCure Q2 net loss narrows on lower expenses
Brief: NextCure Q2 Net Income USD -14.892 Million
NextCure Inc expected to post a loss of $1.93 a share - Earnings Preview